Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

• Egile Nagusiak: Ju Li (Egilea), Zhongyuan Zhang (Egilea), Xinhua Wu (Egilea), Jie Zhou (Egilea), Deqian Meng (Egilea), Ping Zhu (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Adalimumab, golimumab, infliximab, certolizumab, and etanercept are five anti-tumor necrosis factor (anti-TNF) medicines that have been approved for use in rheumatology. Apart from their well-established therapeutic usefulness, -it is unclear to what extent -they are linked to an increas...